The role of enhanced fluorodeoxyglucose F 18 uptake of giant cell tumor of bone (GCTB) should be mentioned in an overview such as that reported by van der Heijden et al., with regard not only to the response to denosumab treatment for unresectable GCTB but also to the clinical implications for the diagnosis of this disease.